{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:02:46Z","timestamp":1789225366490,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,5]],"date-time":"2026-12-05T00:00:00Z","timestamp":1796428800000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jtct.2025.08.026","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T16:55:24Z","timestamp":1757350524000},"page":"1031.e1-1031.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Primary Plasma Cell Leukemia in Japan"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9029-4851","authenticated-orcid":false,"given":"Masaya","family":"Maegaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8731-3469","authenticated-orcid":false,"given":"Tsutomu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Minakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6728-3346","authenticated-orcid":false,"given":"Toshiki","family":"Terao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6007-6264","authenticated-orcid":false,"given":"Atsushi","family":"Satake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangaishi","family":"Akira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Oyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4866-9307","authenticated-orcid":false,"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9091-791X","authenticated-orcid":false,"given":"Nobuyuki","family":"Aotsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Tabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Nawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Ohbiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9976-9787","authenticated-orcid":false,"given":"Koji","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2025.08.026_bib0001","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41375-023-02100-x","article-title":"Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States","volume":"38","author":"Ludovic","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2025.08.026_bib0002","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-021-00414-6","article-title":"A clinical perspective on plasma cell leukemia; current status and future directions","volume":"11","author":"Tuazon","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2025.08.026_bib0003","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.annonc.2025.01.022","article-title":"European Myeloma Network Group Review and Consensus Statement on Primary Plasma Cell Leukemia","volume":"36","author":"Musto","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2025.08.026_bib0004","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(23)00405-9","article-title":"Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12\/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study","volume":"24","author":"van de Donk","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2025.08.026_bib0005","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ajh.26891","article-title":"Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group","volume":"98","author":"Katodritou","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2025.08.026_bib0006","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1038\/s41375-020-0830-0","article-title":"Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era","volume":"34","author":"Dhakal","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2025.08.026_bib0007","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s11912-024-01563-0","article-title":"Current Status on Management of Primary Plasma Cell Leukemia","volume":"26","author":"Gong","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jtct.2025.08.026_bib0008","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3324\/haematol.2021.280568","article-title":"Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling","volume":"108","author":"Lawless","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2025.08.026_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107640","article-title":"Outcomes of hematopoietic stem cell transplantation in primary plasma cell leukemia: A systematic review and meta-analysis","volume":"148","author":"Shahzad","year":"2025","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtct.2025.08.026_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","article-title":"Introduction of transplant registry unified management program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)","volume":"103","author":"Atsuta","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2025.08.026_bib0011","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"Fern\u00e1ndez de Larrea","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2025.08.026_bib0012","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017","journal-title":"Revised"},{"key":"10.1016\/j.jtct.2025.08.026_bib0013","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2025.08.026_bib0014","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.08.026_bib0015","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.08.026_bib0016","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.08.026_bib0017","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.08.026_bib0018","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.08.026_bib0019","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/leu.2011.312","article-title":"Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research","volume":"26","author":"Mahindra","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2025.08.026_bib0020","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2015.63.1929","article-title":"Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du My\u00e9lome","volume":"34","author":"Royer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.08.026_bib0021","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2025.08.026_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106687","article-title":"Plasma cell leukemia: a review of the molecular classification, diagnosis, and evidenced-based treatment","volume":"111","author":"Gowin","year":"2021","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtct.2025.08.026_bib0023","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bjh.15092","article-title":"Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients","volume":"180","author":"Jurczyszyn","year":"2018","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.08.026_bib0024","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1182\/blood-2024-200267","article-title":"Impact of multiple high-risk cytogenetic abnormalities on the survival outcomes of patients with primary plasma cell leukemia","volume":"144","author":"Adrian A Almodovar Diaz","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.08.026_bib0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.mayocp.2020.06.060","article-title":"Clinical characteristics and outcomes of patients with primary plasma cell leukemia in the era of novel agent therapy","volume":"96","author":"Nandakumar","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jtct.2025.08.026_bib0026","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1007\/s00277-024-05862-1","article-title":"Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort study","volume":"103","author":"Deng","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2025.08.026_bib0027","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2025.08.026_bib0028","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12185-023-03602-1","article-title":"Maintenance therapy after allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma","volume":"118","author":"Kawamura","year":"2023","journal-title":"Int J Hematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T10:22:01Z","timestamp":1770805321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725014022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2666636725014022"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.08.026","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Primary Plasma Cell Leukemia in Japan","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}